RT Journal Article
SR Electronic
T1 Are there differences between men and women prescribed bisphosphonate therapy in canadian subspecialty osteoporosis practices?
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 1993
OP 1995
VO 31
IS 10
A1 Anna M Sawka
A1 Jonathan D Adachi
A1 Alexandra Papaioannou
A1 Lehana Thabane
A1 George Ioannidis
A1 K Shawn Davison
A1 Wojciech P Olszynski
A1 Jacques P Brown
A1 David A Hanley
A1 Tim M Murray
A1 Robert G Josse
A1 Rolf J Sebaldt
A1 Annie Petrie
A1 Alan Tenenhouse
A1 Charles H Goldsmith
YR 2004
UL http://www.jrheum.org/content/31/10/1993.abstract
AB OBJECTIVE: To determine if there are differences between men and women referred for treatment of osteoporosis in Canada. METHODS: We performed an observational study of 1588 patients (163 men, 1425 women), 50 years of age and older, who were prescribed cyclic etidronate or alendronate for treatment of osteoporosis or osteopenia and had at least 2 years of followup registered in the Canadian Database for Osteoporosis and Osteopenia Patients (CANDOO). Comparisons of characteristics between men and women were performed using Pearson chi-square test, Student's t test, or a Kruskal-Wallis test, whichever was most appropriate. RESULTS: Mean baseline femoral neck and lumbar spine bone mineral densities were significantly higher in men than women at both the femoral neck and lumbar spine (p < 0.05, respectively). Men had double the rate of prevalent vertebral fractures (44%, 72/163) compared to women (22%, 315/1425; p < 0.001) and triple the rate of multiple prevalent vertebral fractures (10%, 17/163) compared to women (3%, 37/1425, p < 0.001). Furthermore, men were twice as likely as women to sustain a fracture within 2 years of starting treatment during observation in the CANDOO study (men: 4%, 7/163, women: 2%, 24/1425, p = 0.033). CONCLUSION: Osteoporosis may be under-recognized in men until the condition is at an advanced stage. A form of gender bias may exist in recognition and treatment (or referral for treatment) of osteoporosis in men.